ALK and non-small cell lung carcinoma: Herein, we aim to discuss the immune biology of ALK-rearranged NSCLC, mechanisms which lead to immune resistance, and existing pre-clinical and clinical data regarding immunotherapeutic approaches for treatment of ALK-rearranged NSCLC which may inform novel treatment strategies in the future.